Refine
Year of publication
Document Type
- Preprint (269)
- Article (179)
- Working Paper (3)
Language
- English (451)
Has Fulltext
- yes (451)
Is part of the Bibliography
- no (451)
Keywords
- LHC (8)
- Heavy Ion Experiments (6)
- ALICE experiment (4)
- Hadron-Hadron Scattering (3)
- Hadron-Hadron scattering (experiments) (3)
- Heavy Ions (3)
- Heavy-ion collision (3)
- pp collisions (3)
- ALICE (2)
- Beauty production (2)
Institute
- Physik (431)
- Frankfurt Institute for Advanced Studies (FIAS) (396)
- Informatik (379)
- MPI für Biophysik (8)
- Biochemie und Chemie (5)
- Biowissenschaften (5)
- E-Finance Lab e.V. (3)
- Wirtschaftswissenschaften (3)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (2)
- Center for Financial Studies (CFS) (2)
Background: High-dose chemotherapy (HDC) with autologous stem-cell rescue (ASCR) is a treatment option for pediatric patients with relapsed nephroblastoma. We present long term results of 9 patients treated between 1993 and 2013 at our center.
Procedure: Reinduction therapy was carried out according to GPOH and SIOP recommendations. The conditioning regimen consisted of carboplatin (1 200 mg/m²), etoposide (800 mg/m² or 40 mg/kg) and melphalan (180 mg/m²). Purging of the grafts with immunomagnetic CD34 positive selection was performed in 5 patients.
Results: 8 of 9 Patients (90%) are alive without evidence of disease after a median follow-up of 8.5 years. Leukocyte engraftment occurred after a median of 10 days (range 8-12). Median numbers of 667/µl CD3+, 329/µl CD4+, 369/µl CD8+T cells and 949/µl B cells were reached after 180 days. No negative impact of CD34 selection was observed. No transplantation-related death occurred. Acute toxicity comprised mucositis III°-IV° in all and veno-occlusive disease in one patient. Long term effects probably related to treatment occurred in 3/7 evaluable patients and comprised hearing impairment, reduced renal phosphate reabsorption, mild creatinine elevation and hypothyroidism (n=1, each).
Conclusion: Thus, in our experience HDC with ASCR is an effective treatment of recurrent or refractory nephroblastoma with acceptable side effects. However, a randomized trial proving its efficiency with a high level of evidence is needed.